The X-Factors: Three Areas That Will Improve Refractive Cataract Surgery Outcomes

Saturday, April 18, 2015: 5:00 PM-6:30 PM
Hall E, EyeWorld Theater II (San Diego Convention Center)

Supported by unrestricted educational grants from Alcon Laboratories Inc. and Omeros.

Program Chair:  
Edward J. Holland, MD

Preeya K. Gupta, MD
David A. Goldman, MD
Mitchell A. Jackson, MD

5:30 PM  Welcome and Review of Pre-Registrant Survey Data, Opening ARS – Edward J. Holland, MD

5:40 PM  X Factor One: Optimizing the Ocular Surface – The Impact of Ocular Surface Disease on Refractive Cataract Outcomes – Preeya K. Gupta, MD

5:45 PM  Panel Discussion and ARS Assessment – Edward J. Holland, MD

5:50 PM  X Factor Two: Reducing Residual Error – Strategies and Protocols to Prevent Residual Error – Preeya K. Gupta, MD

5:55 PM  Panel Discussion on Protocols and ARS Assessment – Edward J. Holland, MD

6:05 PM  X Factor Three: Reducing Post-operative Inflammation – Strategies to Prevent Edema and Relieve Pain by Maximizing the Penetration of Anti-Inflammatory Agents – David A. Goldman, MD

6:15 PM  X-Factor Three Continued: Reducing Post-operative Inflammation – The Clinical Impact of Ultrasound Energy Applied During Refractive Cataract Surgery – Mitchell A. Jackson, MD

6:25 PM  Final panel discussion and ARS Assessment – Edward J. Holland, MD

6:30 PM  Conclude

Educational Objectives

Ophthalmologists who attend this course will:

  • Distinguish predisposing factors putting patients at higher risk for inflammatory reaction after cataract surgery
    • Review key Uveitis, Retina and Corneal issues
  • Identify the true impact of ocular inflammation levels on outcomes in refractive cataract surgery:
    • Variability in visual acuity and quality results
    • Delayed visual recovery that reduces the postoperative wow factor
    • Pain and discomfort that reduce patient satisfaction
  • Develop personal protocol for acceptable levels of inflammation for post-cataract surgery, as guided by ASCRS leadership
  • Identify new agents and acquire strategies to eliminate inflammation and relieve pain by maximizing the penetration of anti-inflammatory agents into target issues
    • Dosing levels, interventional timing, concomitant therapies and duration to address ocular inflammation
    • Key vehicle parameters including viscosity and other key considerations in selecting the appropriate formulations
    • Patient adherence to regimen
  • Assess the clinical impact of various levels of ultrasound energy applied during cataract surgery, and how these differ with complex vs. routine cataract patients
    • Recognize the amount of reduction in these levels available with laser cataract technology for specific types of patients

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Society of Cataract and Refractive Surgery (ASCRS) and EyeWorld news magazine. ASCRS is accredited by the ACCME to provide continuing medical education for physicians. ASCRS takes responsibility for the content, quality, and scientific integrity of this CME activity.

Designation Statement

The American Society of Cataract and Refractive Surgery designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity. 

All CME activities approved for AMA PRA Category 1 Credit™ are valid for recognition by the European Accreditation Council for Continuing Medical Education (EACCME). Physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 Credit™

Attendees registered as exhibitors, spouses, and guests are not eligible for CME credits.

Notice of Off-Label Use Presentations

This program may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he/she wishes to use in clinical practice. ASCRS is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations of off-label uses, does not imply an endorsement by ASCRS of the uses, products, or techniques presented.

ADA/Special Accommodations

ASCRS fully complies with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. ASCRS also requires ADA compliance from its contracted vendors and facilities. Any participant in this educational program who requires special accommodation or services should contact an ASCRS or EyeWorld staff member onsite.

Edward J. Holland, MD
Preeya K. Gupta, MD , David A. Goldman, MD and Mitchell A. Jackson, MD
See more of: EyeWorld CME Education